At the time of writing, Lexaria Bioscience Corp [LEXX] stock is trading at $2.55, up 6.25%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LEXX shares have gain 13.33% over the last week, with a monthly amount glided 70.00%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 16, February 2024, Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules. In a post published today on Yahoo Finance, Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq;LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.31 per share (or per common stock equivalent in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 1,558,443 shares of common stock at an exercise price of $2.185 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.
From an analyst’s perspective:
For the past year, the stock price of Lexaria Bioscience Corp fluctuated between $0.65 and $3.60. Lexaria Bioscience Corp [NASDAQ: LEXX] shares were valued at $2.55 at the most recent close of the market.
Analyzing the LEXX fundamentals
According to Lexaria Bioscience Corp [NASDAQ:LEXX], the company’s sales were 0.34M for trailing twelve months, which represents an 36.10% jump. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -21.39%, Pretax Profit Margin comes in at -22.2%, and Net Profit Margin reading is -22.06%. To continue investigating profitability, this company’s Return on Assets is posted at -1.68, Equity is -1.51 and Total Capital is -1.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.38 points at the first support level, and at 2.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.83, and for the 2nd resistance point, it is at 3.12.
Lexaria Bioscience Corp [LEXX] reported earnings per share of -$0.13 for its fiscal quarter that ended on 11/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.11/share, meaning a difference of -$0.02 and a surprise factor of -18.20%. By comparison, the stated earnings for the previous quarter ended on 8/30/2023 were -$0.12 per share as compared to estimates of -$0.13 per share, a difference of $0.01 representing a surprise of 7.70%.
Ratios To Look Out For
It is important to note that Lexaria Bioscience Corp [NASDAQ:LEXX] has a current ratio of 21.63. As well, the Quick Ratio is 21.63, while the Cash Ratio is 15.69. Considering the valuation of this stock, the price to sales ratio is 91.57, the price to book ratio is 7.03.
